Colorectal Cancer Clinical Trials

163 studies are recruiting for colorectal cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

   This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for s…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

   Locations

   11 in total

   Run by

   Phanes Therapeutics

   See if you can join NCT05482893 on ClinicalTrials.gov

2. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology, Beverly Hills, California

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

3. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

   TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

   Stage

   Phase 2

   Ages

   18 to 130

   Site

   Research Site, Los Angeles, California

   Locations

   96 in total

   Run by

   AstraZeneca

   See if you can join NCT05489211 on ClinicalTrials.gov

4. Precise Oncology Interventions in Nutrition and Training (OnPoint)

   The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT06534918 on ClinicalTrials.gov

5. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC IRVINE Health, Orange, California

   Locations

   56 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06128551 on ClinicalTrials.gov

6. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ironwood Cancer and Research Centers, Chandler, Arizona

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

7. A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

   The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residu…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07227636 on ClinicalTrials.gov

8. Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

   A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent. Subjects will be provided 21 days of standardized High-fiber/low-fat meals and complete a food diary …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT06349590 on ClinicalTrials.gov

9. Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

   The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs, Council Bluffs, Iowa

   Locations

   13 in total

   Run by

   Exelixis

   See if you can join NCT07750158 on ClinicalTrials.gov

10. GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

    There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setti…

    Stage

    EARLY_Phase 1

    Ages

    18 to 99

    Site

    University of Arizona Cancer Center, Tucson, Arizona

    Run by

    University of Arizona

    See if you can join NCT07627191 on ClinicalTrials.gov

11. Tislelizumab in People With Colorectal Cancer

    The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet rece…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    3 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06529523 on ClinicalTrials.gov

12. Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

    The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is: • Does the management of this condition with uninterrupted palliative…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07044362 on ClinicalTrials.gov

13. SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

    The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outco…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Orchard Healthcare Research Inc., Skokie, Illinois

    Run by

    Guardant Health, Inc.

    See if you can join NCT05935384 on ClinicalTrials.gov

14. Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

    This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer. The name…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06202183 on ClinicalTrials.gov

15. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

    The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT04899908 on ClinicalTrials.gov

16. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

17. Personalized Health Self-Management Training for Colorectal Cancer Survivors

    This is a Phase 2 prospective, randomized, controlled, double-arm study to assess personalized self-management training (PSMT) intervention efficacy and patient experiences compared to standardized self-management training (SSMT). A total of 120 gastrointestinal (GI) cancer patients will be enrolle…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    2 in total

    Run by

    University of Southern California

    See if you can join NCT05984589 on ClinicalTrials.gov

18. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    5 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

19. Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

    To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07071961 on ClinicalTrials.gov

20. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, San Diego, California

    Locations

    9 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

21. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

    This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    10 in total

    Run by

    Cartography Biosciences

    See if you can join NCT07321106 on ClinicalTrials.gov

22. Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

    To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06617858 on ClinicalTrials.gov

23. Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

    The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and …

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Colorado Denver, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT05517811 on ClinicalTrials.gov

24. Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

    This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Roswell Park Cancer Institute, Buffalo, New York

    Run by

    Roswell Park Cancer Institute

    See if you can join NCT03965234 on ClinicalTrials.gov

25. Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

    The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.

    Stage

    Not phased

    Ages

    65 and older

    Site

    Froedtert Hospital, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT07227077 on ClinicalTrials.gov